<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Virology Journal                                                                                                                         BioMed Central <br />  <br />  <br />  <br /> Research                                                                                                                               Open Access <br /> Stable replication EBNA1/OriP-mediated baculovirus vector application anti-HCV gene therapy <br /> Hitoshi Suzuki1, Norihiko Matsumoto1, Tomoyuki Suzuki1, <br /> Myint OO Chang1 Hiroshi Takaku*1,2 <br />  <br /> Address: 1Department Life Environmental Sciences, Chiba Institute Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan 2High Technology Research Center, Chiba Institute Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan <br /> Email: Hitoshi Suzuki - g0473021FE chiba.ac.jp; Norihiko Matsumoto - norihiko.matsumoto chiba.ac.jp; <br /> Tomoyuki Suzuki - s026079RN chiba.ac.jp; Myint OO Chang - c_myintoo@hotmail.com; Hiroshi Takaku* - hiroshi.takaku chiba.ac.jp <br /> * Corresponding author <br />  <br />  <br />  <br />  <br /> Published: 2 October 2009                                                   Received: 24 June 2009 <br />                                                                             Accepted: 2 October 2009 <br /> Virology Journal 2009, 6:156   doi:10.1186/1743-422X-6-156 article available  http://www.virologyj.com/content/6/1/156 <br /> &#194;&#169; 2009 Suzuki et al; licensee BioMed Central  Open Access article distributed terms Creative Commons Attribution License (http://creativecommons.org/licenses 2.0), permits unrestricted use, distribution, reproduction medium, provided original work properly cited. <br />  <br />  <br />  <br />  <br />                   Abstract <br />                   Background: Hepatitis C virus (HCV) main causes liver-related morbidity                   mortality. combined interferon-&#206;&#177;-ribavirin therapy effective 50%                   patients HCV, better therapies needed preventative vaccines                   developed. Short-hairpin RNAs (shRNAs) inhibit gene expression RNA interference.                   application transient shRNA expression limited,  inability shRNA <br />                   replicate mammalian cells inefficient transduction. duration transgene (shRNA) <br />                   expression mammalian cells significantly extended using baculovirus-based shRNA- <br />                   expressing vectors contain latent viral protein Epstein-Barr nuclear antigen 1 (EBNA1)                   origin latent viral DNA replication (OriP) sequences. recombinant vectors contain <br />                   compatible promoters highly effective infecting primary hepatocyte hepatoma cell <br />                   lines, making useful tools studies hepatitis B hepatitis C viruses.                    report use baculovirus-based vector-derived shRNAs inhibit core-protein <br />                   expression length hepatitis C virus (HCV) replicon cells. <br />                   Results: constructed long-term transgene shRNA expression vector contains EBV <br />                   EBNA1 OriP sequences. designed baculovirus vector-mediated shRNAs                   highly conserved core-protein region HCV. HCV core protein expression inhibited                   EBNA1/OriP baculovirus vector 14 days, considerably longer 3 days <br />                   inhibition produced wild-type baculovirus vector. <br />                   Conclusion: findings indicate successfully constructed long-term transgene <br />                   (shRNA) expression vector (Ac-EP-shRNA452) using EBNA1/OriP                    propagated Escherichia coli converted mammalian cells. potential anti-HCV activity <br />                   long-term transgene (shRNA) expression vector evaluated view establishing <br />                   highly effective therapeutic agents developed HCV gene therapy <br />                   applications. <br />  <br />  <br />  <br />  <br />                                                                                                                                          Page 1 8 <br />                                                                                                                  (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                            http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br />  <br /> Background                                                          non-covalent attachment host chromosome. Infection hepatitis C virus (HCV) major public-         EBV replicon vector used study long- <br /> health problem, 170 million people chronically                 term transgene expression [22,23]. origin latent <br /> infected worldwide [1,2]. current treatment                viral DNA replication (OriP) [24] latent viral pro- <br /> combined interferon-ribavirin therapy fails cure             tein Epstein-Barr nuclear antigen 1 (EBNA1) [21] essen- <br /> infection 30% 50% cases [3,4], particularly          tial replication EBV [25]. EBNA1/OriP HCV genotypes 1 2. Chronic infection HCV              elements successfully exploited achieve dura- <br /> results liver cirrhosis lead hepatocellular car-      ble expression foreign genes plasmid- virus- <br /> cinoma [5,6]. combined interferon-&#206;&#177;-ribavirin              based expression systems [26-30]. <br /> therapy effective 50% patients infected HCV, better therapies needed preventative              Previously, demonstrated efficient inhibition intracel- <br /> vaccines developed. effort develop          lular HCV replication baculovirus-based shRNA-express- alternative combined interferon-ribavirin treatment,          ing vectors [31]. expression transient, used RNA interference based short-hairpin RNA                  unable provide long-term expres- <br /> (shRNA), powerful tool suppressing gene              sion shRNA. hypothesized long-term trans- <br /> function [7]. Small interference RNAs (siRNAs) directed             gene (shRNA) expression significantly improved HCV likely successfully block replication        mammalian cells using baculovirus-based shRNA-express- <br /> cycle HCV RNA virus replicates             ing vectors containing EBNA1/OriP sequences. <br /> cytoplasm liver cells integration host <br /> genome.                                                             present study, constructed long-term transgene <br />                                                                     (shRNA) expression vector (Ac-EP-shRNA452) using ability baculoviruses, including Autographa califor-         EBNA1/OriP  propagated Escherichia <br /> nica multiple nuclear polyhedrosis virus (AcMNPV), infect        coli converted mammalian cells. potential <br /> insect cells led use multiple protein expres-       anti-HCV activity long-term transgene (shRNA) <br /> sion systems [8,9] plant insecticides [10]. AcMNPV,          expression vector evaluated view estab- genome comprises circular, double-                   lishing highly effective therapeutic agents fur- <br /> stranded DNA contains ~130 Kbp [11] surrounded              ther developed HCV gene therapy applications. large envelope, infects variety mammalian cell <br /> types, exception certain hematopoietic cell             Results <br /> lines, genome does replicate integrate          Construction baculovirus transfer vectors carrying mammalian chromosomes [12,13]. particular,              shRNA-synthesizing cassettes <br /> inability baculoviruses replicate mammalian cells          core-protein forms nucleocapsid modulates <br /> makes attractive candidate vectors vitro gene           gene transcription, cell proliferation, apoptosis. HCV <br /> therapy studies [14,15]. recombinant vectors              functions mRNA single-stranded RNA <br /> tain compatible promoters highly effective               genome;  hypothesized cleavage core- <br /> infecting primary hepatocyte hepatoma cell lines,               protein mRNA inhibit nuclear transport virus <br /> making useful tools studies hepatitis B            duplication. previously reported design baculo- hepatitis C viruses [16-18].                                    virus vectors expressing shRNA following <br />                                                                     region HCV: 452-472, contains nuclear major limitation baculoviral transduction vector,          localization signal site HCV core region (Figure 1A,  short duration transgene expression.             B) [31]. vector   induce long-term baculovirus genome replicate mam-             shRNA expression.  constructed long-term <br /> malian cells, usually lost diluted soon infection.   transgene shRNA expression vector contains EBV efficiency transgene expression substantially        EBNA1 OriP sequences (Figure 1C). Recombinant <br /> increased applicable human gene therapy [19].             baculovirus containing shRNA genome (Ac-shRNA Epstein Barr virus (EBV) plasmid replicating episo-        Ac-EP-shRNA) generated homologous recom- <br /> mal vector developed overcome prob-            bination transfer vector linearized baculovirus <br /> lem rapid elimination intracellularly-delivered               DNAs (BD Biosciences, San Jose, CA) Sf9 cells. Viruses <br /> plasmid DNA nonviral vector-mediated gene transfer.              produced high titers, ranging 2.0 &#195;&#8212; 108 4.5 <br /> EBV gamma herpes virus maintained ~172-           &#195;&#8212; 108 pfu/ml. <br /> kb episome small ratio resting B cells epithelial <br /> cells human population. EBV induces latent           Inhibition HCV RNA replication EBNA1/OriP <br /> infection human B cells [20]. EBV infects cells,        baculovirus-mediated shRNA-expression vectors linear double-stranded genomes circularized             HCV replicon <br /> sustained stable episome. EBV replication           investigated intracellular expression present 1~100 copies cell [21], separates       shRNA inhibited viral replication affected HCV RNA <br />  <br />                                                                                                                          Page 2 8 <br />                                                                                                  (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                     http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br />  <br /> Figure Genomic <br />         1 profile HCV showing coding non-coding genes Genomic profile HCV showing coding non-coding genes. B HCV core region target sites sequences used design shRNAs. C Construction schematic representation EBNA1/OriP baculovirus transfer <br /> vector expressing HCV core shRNA. <br />  <br />  <br />  <br /> levels NNC#2 cells. baculovirus-infection effi-       protein expression significantly reduced compared <br /> ciency NNC#2 cells ranged 80% 90% [31].           scrambled shRNA control (Ac-EP-control-shRNA) <br /> Real-time reverse transcription polymerase chain reaction    3 days (data shown). Ac-shRNA452 Ac- <br /> (RT-PCR) used examine ability silence RNA      EP-shRNA inhibited HCV replication 3 days (Figure NNC#2 cells 3 days post-infection. NNC#2 cells       3A). 3 days,  cells infected Ac- infected Ac-shRNAs multiplicity infec-     shRNA452 exhibited steady increase HCV RNA <br /> tion (MOI) 50 100, HCV RNA levels signifi-       expression infected Ac-EP-shRNA452 <br /> cantly reduced compared scrambled shRNA               continued low HCV RNA expression 14 <br /> control. constructs, Ac-shRNA452 (55%, MOI        days (Figure 3A). Infection NNC#2 cells 50; 71%, MOI 100) Ac-EP-shRNA452 (55%, MOI 50;           recombinant baculovirus vectors containing genetic ele- <br /> 67%, MOI 100), inhibited HCV RNA levels (Figure          ments EBV, EBNA1, OriP did induce cellular <br /> 2A). contrast, control baculovirus vector (Ac-EP-     toxicity, determined bromodeoxyuridine <br /> control-shRNA) did inhibit HCV replication (Figure       (BrdU)-based colorimetric assay (Figure 3B). results <br /> 2A). findings indicated shRNA           suggest HCV RNA expression effectively <br /> sequence-specific inhibitory effect HCV replication.      inhibited EBNA/OriP baculovirus vector used CLEIA assay examine shRNA        wild-type baculovirus vector. HCV core protein inhibited viral replication. NNC#2 cells infected Ac-shRNAs MOIs        Production EBNA1 protein siRNA baculovirus- 50 100, core-protein expression significantly     based shRNA-expressing vectors containing EBNA1/OriP <br /> reduced compared non-related shRNA control (Fig-      sequences <br /> ure 2B). Ac-EP-control-shRNA baculovirus vectors         used Western blot analysis detect EBNA1 pro- inhibitory effect HCV replication.                 tein Ac-EP-shRNA-infected cells (Figure 4A). EBNA1 <br />                                                              protein detected Ac-EP-shRNA-infected cells. <br /> Enhanced baculovirus-mediated shRNA effects              investigate HCV core gene-targeting shR- <br /> observed presence EBNA1/OriP                       NAs digested mono-specific products investigate effect EBNA/OriP shRNA expres-      expected size, siRNAs analyzed Northern blot <br /> sion, examined inhibition HCV replication       analysis shRNA-expressing NNC#2 cells. siRNAs <br /> Ac-shRNA452 Ac-EP-shRNA452 NNC#2 cells            Ac-shRNA452 Ac-EP-shRNA452 yielded <br /> 14 days. NNC#2 cells infected Ac-      products ~20 nt, expected size mono- <br /> shRNA452 Ac-EP-shRNA452 MOI 100, core-           meric siRNAs, 3 days (Figure 4B). siRNA band  <br />  <br />                                                                                                                   Page 3 8 <br />                                                                                           (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                        http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br />  <br /> Figure 2 HCV RNA EBNA1/OriP wild-type baculovirus-mediated sh452 <br /> Inhibition <br /> Inhibition HCV RNA EBNA1/OriP wild-type baculovirus-mediated sh452. Real time PCR analysis HCV RNA expression transduction HCV replicon cells (NNC#2, 4 &#195;&#8212; 104 cells  MOI 50 100 bacu- <br /> lovirus-mediated shRNA. HCV RNA values relative scrambled shRNA control shown. B Inhibition HCV replica- <br /> tion baculovirus-mediated core shRNAs. Ac-shRNAs used infect HCV replicons intracellular HCV core protein <br /> levels measured 3 days HCV protein antigen CLEIA assay. Error bars represent standard errors mean experiments. *p &lt; 0.01. <br />  <br />  <br /> Ac-shRNA452-infected cells,  undetecta-          OriP effective useful long-term high- <br /> ble 5 days. contrast, siRNA Ac-EP-shRNA452-         level transgene expression. <br /> infected cells detected 14 days. <br />                                                                 study, recombinant baculovirus vectors containing <br /> Discussion                                                      genetic elements EBV, EBNA1/OriP, high demand development effective           essential episomal maintenance EBV <br /> anti-HCV drugs. Gene silencing RNA interference         genome latently infected cells, constructed promising approach elucidate gene function            tested ability sustain express transgene <br /> inhibit certain RNA viruses HCV [32-34]. Delivery       (enhanced HCV core gene-targeting shRNAs) HCV rep- siRNA appropriate cells tissues,      licon cells. introduction wild-type EBNA1/OriP- <br /> major challenge. approaches described         baculovirus-mediated sh452 target cells containing generating loss function phenotypes mammalian         HCV replicon RNA induced dose-related reduction systems using siRNA, techniques limited       level HCV RNA 3 days. effectiveness suitable generating long-term silencing effect    inhibition HCV replication,  did differ vivo [35,36]. Efficient safe delivery systems   control different vectors (Ac- established suppression HCV replica-        shRNA452 Ac-EP-shRNA452). <br /> tion. Baculoviruses appear useful viral vectors, abundant expression foreign genes            investigate long-term effect EBNA/OriP insect cells, efficient gene delivery       shRNA expression, examined inhibition HCV <br /> hepatoma lines HepG2 Huh7 [37]. major            replication Ac-shRNA452 Ac-EP-shRNA452 limitations baculoviral transduction vector       NNC#2 cells 14 days. Ac-shRNA452 Ac-EP- <br /> short duration transgene expression. EBNA1/OriP          shRNA inhibited HCV replication 3 days. 3 days, widely exploited different vec-          cells infected Ac-shRNA452 exhibited tors cell lines. findings suggest EBNA1/       steady increase HCV RNA expression  <br />  <br />                                                                                                                       Page 4 8 <br />                                                                                               (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                      http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br />                                                                EP-shRNA-infected cells. findings indicated direct <br />                                                                correlation level virus siRNA                                                                EBNA1 production. <br />  <br />                                                                Conclusion <br />                                                                results present study indicate suc- <br />                                                                cessfully constructed long-term transgene (shRNA) <br />                                                                expression vector (Ac-EP-shRNA452) using EBNA1/ <br />                                                                OriP  propagated Escherichia coli                                                                converted mammalian cells. potential anti-HCV <br />                                                                activity long-term transgene (shRNA) expression <br />                                                                vector evaluated view establishing highly <br />                                                                effective therapeutic agents developed <br />                                                                HCV gene therapy applications. <br />  <br />                                                                Methods <br />                                                                Cell culture <br />                                                                NNC#2 (NN/1b/FL) cells [38] carrying genome rep- <br />                                                                licon cultured Dulbecco&apos;s modified Eagle&apos;s <br />                                                                medium supplemented 10% fetal bovine serum, <br />                                                                non-essential amino-acids, <span id='am-10' about='obo:IMR_0200448' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0001695 obo:IMR_0000001'><span id='am-11' property="rdfs:label" content="L-Glutamine" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasDbXref" content="KEGG:C00064" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:id" content="IMR:0200448" datatype="xsd:string"></span>L-glutamine</span>, 1 mg/ml <br />                                                                G418 (Invitrogen, Carlsbad, CA). <br />  <br />                                                                Northern blot analysis <br />                                                                Total RNA extracted Ac-shRNA452 infected <br /> type <br /> Long-term <br /> Figure  3 inhibition HCV <br />      baculovirus-mediated  sh452 <br />                               RNA EBNA1/OriP wild- <br />                                                                Huh7 cells using mirVana&#226;&#8222;&#162; miRNA Isolation Kit, <br /> Long-term inhibition HCV RNA EBNA1/OriP wild-type baculovirus-mediated sh452. Real-              according manufacturer&apos;s instructions (Roche Diag- <br /> time RT-PCR analysis HCV RNA expression trans-        nostics GmbH, Mannheim, Germany). Small RNAs (5 &#206;&#188;g) <br /> duction HCV replicon cells (NNC#2, 4 &#195;&#8212; 104 cells/      loaded 15% (w/v) polyacrylamide/7 M <span id='am-15' about='obo:IMR_0200111' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-16' property="oboInOwl:id" content="IMR:0200111" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasDbXref" content="KEGG:C00086" datatype="xsd:string"></span><span id='am-19' property="rdfs:label" content="Urea" datatype="xsd:string"></span>urea</span>  Ac-shRNA452 (MOI = 100 [circle]), Ac-EP-            gel. transfer Hybond-N&#226;&#8222;&#162; nylon membrane (GE <br /> shRNA452 (MOI = 100 [square]). B cytotoxicity Ac-       Healthcare Bio-Sciences Corp., Piscataway, NJ), synthetic <br /> EP-shRNA452 (square) Ac-shRNA452 (circle) repre-           locked nucleic acid (LNA)/DNA oligonucleotides (sh452: <br /> sented percentage reduction viable Huh-7 cells.    5&apos;-DIG-CCGCGCAGGGGCCCCAGG-3&apos;) complementary <br /> cytotoxicity assay performed using BrdU Cell Prolifer-   antisense strand shRNA452 used ation ELISA kit according manufacturer&apos;s instructions   probes. membranes prehybridized 1 h (Roche Diagnostics GmbH). toxicity results repre-      DIG EASY hybridization buffer (Roche Diagnostics <br /> sentative independent experiments. <br />                                                                GmbH) 60&#194;&#176;C hybridized overnight 5&apos;-DIG <br />                                                                labeled LNA/DNA probe (10 ng/ml hybridization <br /> infected Ac-EP-shRNA452 continued low             buffer). post-hybridization washes performed <br /> HCV RNA expression 14 days. recom-          20 min 60&#194;&#176;C 2&#195;&#8212; SSC (1&#195;&#8212; SSC = 0.15 M <br /> binant baculovirus vectors containing genetic elements         NaCl plus 0.015 M sodium citrate-0.1% sodium dodecyl EBV, EBNA1, OriP did induce cellular toxic-       sulfate). LNA/DNA/RNA hybrids detected using ity NNC#2 cells, determined BrdU-based        CSPD chemiluminescent detection (Roche Diag- <br /> colorimetric assay. HCV RNA inhibited               nostics GmbH). <br /> EBNA1/OriP baculovirus-mediated shRNA452 longer time EBNA1/OriP baculovirus vector          Western blot analysis wild-type baculovirus vector.                           Cells lysed 1&#195;&#8212; CAT enzyme-linked immunosorb- <br />                                                                ent assay buffer (Roche Diagnostics GmbH). Cell lysates investigate EBNA1/OriP baculovirus-medi-            separated sodium dodecyl sulfate/polyacrylamide <br /> ated shRNA452 digested mono-specific prod-           gel electrophoresis transferred nitrocellulose mem- <br /> ucts expected size, monomeric siRNAs performed         branes, blocked PVDF Blocking Rea- Northern blot analysis AB1-shRNA expressing              gent (TOYOBO, Ohsaka, Japan). primary antibodies <br /> NNC#2 cells. shRNAs yielded products ~20 nt,           used monoclonal antibodies EBNA1 (Acris <br /> expected size monomeric siRNAs, long term.         Antibodies GmbH) G3PDH (Santa Cruz Biotechnol- <br /> Furthermore, EBNA1 protein detected Ac-        ogy, , Santa Cruz, CA). Horseradish peroxidase-conju- <br />  <br />  <br />                                                                                                                     Page 5 8 <br />                                                                                             (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                         http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br />  <br /> Figure 4 EBNA1 protein siRNA Ac-EP-shRNA452 infected cells <br /> Detection <br /> Detection EBNA1 protein siRNA Ac-EP-shRNA452 infected cells. Western blot analysis EBNA1 <br /> expression baculovirus-infected Huh7 cells. Cell lysates prepared 7 days 14 days post-infection cells infected different viruses. Lane 1: Ac-sh452; lane 2: Ac-EP-sh452; lane 3: Ac-EP-control-shRNA. B Expression siRNA bacu- <br /> lovirus vector. demonstrate intracellular expression shRNA construct respective siRNA, Huh-7 cells infected Ac-EP-shRNA452. mixture run 15% polyacrylamide TBE urea gel 3, 7, 14 days. <br />  <br />  <br /> gated anti-goat antibody (Sigma <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="chemical" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span>Chemical</span> , St. Louis,         Baculovirus transfer vector constructs <br /> MO) used secondary antibody.                          designed baculovirus transfer vectors expressing shR- <br />                                                                  NAs following region HCV core-protein <br /> RNA purification real-time RT-PCR                            sequence: nucleotides 452-472, contains Total RNA isolated cells using mirVana            nuclear localization signal site (pU6-core-shRNA452) <br /> miRNA Isolation Kit (Ambion, Austin, TX). Real-time RT-          [31]. following site core region common <br /> PCR performed using following primers located            sequence HCV strain M1LE (GenBank accession HCV core region: forward primer (813-833 nt), 5&apos;-         number AB080299) chosen target CTGGAGGACGGCGTGAATTAT-3&apos;; reverse primer (938-                   shRNA:            5&apos;-GCCGCGCAGGGGCCCCAGGUU-3&apos; <br /> 957 nt), 5&apos;-CGTTCGTGACATGGTATATC-3&apos;. HCV-specific                (shRNA452). Sense antisense strands shRNA oligo- <br /> RNA detected real-time PCR increase SYBR         nucleotides synthesized, annealed 95&#194;&#176;C 3 min, <br /> Green fluorescence ABI PRISM 7700 (Applied Bio-          slowly cooled phosphate-buffered saline (pH <br /> systems, Foster City, CA). 18S rRNA housekeeping             7.4, containing 50 mM NaCl). oligonucleotides  <br /> gene used control normalization. real-         tained loop CCACACC sequence, KpnI time PCR assay performed triplicate.                      BamHI ends, inserted pU6 vector, based <br />                                                                  pSV2-neo. Pol III-type U6 promoter allowed  <br /> Cytotoxicity assay                                               stant expression shRNAs. Fragments U6-core- <br /> NNC#2 cells (2 &#195;&#8212; 104 cells/mL) seeded 96          sh452, ranging EcoRI site upstream U6 <br /> microtiter plates incubated presence various       promoter BamHI site downstream terminat- <br /> concentrations test compounds. dilutions              ing sequence, sequenced inserted ranged 1 5-fold, 9 concentrations exam-         cloning site baculovirus transfer vectors pVL1392 <br /> ined. experiments performed triplicate.       pVL1393 (BD Biosciences, San Jose, CA) oppo- 3 days culture 37&#194;&#176;C <span id='am-5' about='obo:IMR_0200324' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-6' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasDbXref" content="KEGG:C00011" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:id" content="IMR:0200324" datatype="xsd:string"></span><span id='am-9' property="rdfs:label" content="CO2" datatype="xsd:string"></span>CO2</span> incubator, cell        site orientation polyhedrin promoter create <br /> bility quantified using colorimetric BrdU Cell Pro-        pVL1392-core-shRNA452 pVL1393-core-shRNA452. <br /> liferation enzyme-linked immunosorbent assay according           spacer inserted inverted sequences manufacturer&apos;s instructions (Roche Diagnostics            form hairpin structure, enhance stability. <br /> GmbH). absorbances read microcomputer- <br /> controlled photometer (Titertec MultiscanR; Labsystem            EBV EBNA1 OriP gene sequences obtained <br /> Oy, Helsinki, Finland) 405 nm. values         pCEP4 plasmid (Invitrogen). EBNA1/OriP <br /> translated percentages                             sequence digested restriction enzymes EcoRI  <br />                                                                                                                        Page 6 8 <br />                                                                                                (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                                            http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br /> SalI, inserted EcoRI XhoI sites pVAX1                      opment Program New Bio-industry Initiatives Ministry (Invitrogen). cytomegalovirus (CMV) promoter                           Agriculture Forestry, Fisheries Japan. <br /> amplified PCR using pCEP4 template. CMV <br /> promoter inserted HindIII EcoRI sites                         References <br />                                                                                1.    Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, <br /> upstream EBNA1/OriP sequence. CMV-EBNA1/                                  Kuo G: Detection antibody hepatitis C virus prospec- <br /> OriP unit digested PmeI, inserted                              tively followed transfusion recipients acute chronic <br /> NaeI site baculovirus transfer plasmid pVL1392                                non  non-B hepatitis. N Eng J Med 1989, 321:1494-1500. <br />                                                                                2.    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: <br /> (BD Biosciences) construct pVL1392-EPCMV. Frag-                                   Isolation cDNA clone derived blood-borne non- <br /> ments U6-core-sh452, ranging NotI site                                    non-B viral hepatitis genome. Science 1989, 244:359-362. <br />                                                                                3.    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi <br /> upstream U6 promoter BamHI site                                   VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa- <br /> stream terminating sequences, sequenced                              2b combination ribavirin initial treatment inserted cloning site pVL1392-EPCMV                             chronic hepatitis C. N Eng J Med 1998, 339:1485-1492. <br />                                                                                4.    Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs <br /> baculovirus transfer vector produce plasmid                                   S, Clement RP: dose-ranging study pegylated interferon <br /> pVL1392-EP-shRNA. Scrambled shRNA (control-shRNA)                                    alfa-2b ribavirin chronic hepatitis C. Hepatology 2000, <br /> cloned vector used negative control                           32:647-653. <br />                                                                                5.    Saito  Miyamura T, Ohbayashi  Harada H, Katayama T, Kikuchi S, <br /> (pVL1392-EP-control-shRNA) experiments.                                       Watanabe Y, Koi S, Onji M, Ohtaet Y: Hepatitis C virus infection <br />                                                                                      associated development hepatocellular carci- <br />                                                                                      noma. Proc Natl Acad Sci USA 1990, 87:6547-6549. <br /> Preparation baculoviruses                                                   6.    Seeff LB: Natural history hepatitis C. Hepatology 1997, <br /> Recombinant baculovirus containing shRNA genome                                  26:21S-28S. <br /> (Ac-shRNA) generated homologous recombina-                              7.    Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short <br />                                                                                      hairpin RNAs (shRNAs) induce sequence-specific silencing tion transfer vector linearized baculovirus                               mammalian cells. Genes Dev 2002, 16:948-58. <br /> DNAs (BD Biosciences) following previously published                           8.    Berger  Fitzgerald DJ, Richmond TJ: Baculovirus expression sys- <br />                                                                                      tem heterologous multiprotein complexes. Nat Biotechnol <br /> procedures [39].                                                                     2004, 22:1583-1587. <br />                                                                                9.    Matsuura Y, Possee RD, Overton HA, Bishop DH: Baculovirus <br /> Measurement HCV core protein                                                      expression vectors: requirements high level expres- <br />                                                                                      sion proteins, including glycoproteins. J Gen Virol 1987, <br /> AcU6-HCV-core-shRNAs Ac-EBNAU6-core-shRNAs                                        68:1233-1250. used infect HCV replicon cells. 3 days, intra-                   10.   Stewart LM, Hirst M, L&#195;&#179;pez Ferber M, Merryweather  Cayley PJ, <br /> cellular HCV core-protein levels measured using                               Possee RD: Construction improved baculovirus insecti- <br />                                                                                      cide containing insect-specific toxin gene. Nature 1991, <br /> fully automated HCV core-protein antigen chemilumines-                               352:85-88. <br /> cent enzyme immunoassay (CLEIA) according                               11.   Ayres MD, Howard SC, Kuzio J, Lopez-Ferber M, Possee RD:                                                                                      complete DNA sequence Autographa californica nuclear <br /> manufacturer&apos;s instructions [40,41]. relative chemilu-                           polyhedrosis virus. Virology 1994, 202:586-605. <br /> minescence unit measured used determine                         12.   Tjia ST, zu Altenschildesche GM, Doerfler W: Autographa califor- <br /> concentration HCV core antigen according                                 nica nuclear polyhedrosis virus (AcNPV) DNA does  <br />                                                                                      sist mass cultures mammalian cells. Virology 1983, <br /> standard curve generated using recombinant HCV core                                  125:107-117. <br /> antigen. concentration expressed units fem-                      13.   Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M: <br />                                                                                      Efficient gene transfer human hepatocytes baculovi- <br /> tomole/L (fmol/L). CLEIA assay performed                                 rus vectors. Proc Natl Acad Sci USA 1995, 92:10099-10103. <br /> triplicate.                                                                    14.   Tani H, Limn CK, Yap CC, Onishi M, Nozaki M, Nishimune Y, Oka- <br />                                                                                      hashi N, Kitagawa Y, Watanabe R, Mochizuki R, Moriishi K, Matsuura <br />                                                                                      Y: vitro vivo gene delivery recombinant baculo- <br /> Competing interests                                                                  viruses. J Virol 2003, 77:9799-9808. authors declare competing interests.                     15.   Yl&#195;&#164;-Herttuala Y, Alitalo K: Gene transfer tool induce <br />                                                                                      therapeutic vascular growth. Nat Med 2003, 9:694-701. <br />                                                                                16.   Delaney 4th, Edwards R, Colledge D, Shaw T, Torresi J, Miller <br /> Authors&apos; contributions                                                               TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini S: Cross- <br /> HS designed study, performed experiments,                             resistance testing antihepadnaviral compounds using <br />                                                                                      novel recombinant baculoviruses encode drug-resist- drafted manuscript. NM participated design                            ant strains hepatitis B virus. Antimicrob Agents Chemother 2001, EBNA1/OriP-baculovirus transfer vector construct                              45:1705-1713. <br /> experiments. TS MOOC, participated design                        17.   McCormick CJ, Rowlands DJ, Harris M: Efficient delivery reg- <br />                                                                                      ulable expression hepatitis C virus length minige- <br /> recombinant baculovirus experiments. HT conceived                                nome constructs hepatocyte-derived cell lines using <br /> study, participated design ordination,                             baculovirus vectors. J Gen Virol 2002, 83:383-394. <br /> helped draft manuscript. authors read                      18.   Fipaldini C, Bellei B, La Monica N: Expression hepatitis C virus <br />                                                                                      cDNA human hepatoma cell line mediated hybrid <br /> approved final manuscript.                                                       baculovirus-HCV vector. Virology 1999, 255:302-311. <br />                                                                                19.   Marshall E: Gene therapy&apos;s growing pains. Science 1995, <br />                                                                                      269:1052-1055. <br /> Acknowledgements                                                               20.   Lindahl T, Adams  Bjursell G, Bornkamm GW, Kaschka-Dierich C, work supported,  Grants Aid research hepa-             Jehn U: Covalently closed circular duplex DNA Epstein- <br /> titis Ministry Health, Labor, Welfare Japan; Grant         Barr virus human lymphoid cell line. J Mol Biol 1976, Supporting Program Creating University Ventures Japan Sci-              102:511-530. <br /> ence Technology Agency; Grant Research Devel- <br />  <br />  <br />                                                                                                                                             Page 7 8 <br />                                                                                                                     (page number citation purposes) <br />  Virology Journal 2009, 6:156                                                                             http://www.virologyj.com/content/6/1/156 <br />  <br />  <br />  <br /> 21.   Yates JL, Warren N, Sugden B: Stable replication plasmids <br />       derived Epstein-Barr virus various mammalian cells. <br />       Nature 1985, 313:812-815. <br /> 22.   Calos MP: potential extra chromosomal replicating <br />       vectors gene therapy. Trends Genet 1996, 12:463-466. <br /> 23.   Kelleher ZT, Fu H, Livanos E, Wendelburg B, Gulino S, Vos JM: <br />       Epstein-Barr-based episomal chromosomes shuttle 100 kb <br />       self-replicating circular human DNA mouse cells. Nat <br />       Biotechnol 1998, 16:762-768. <br /> 24.   Yates J, Warren N, Reisman D, Sugden B: cis-acting element <br />       Epstein-Barr viral genome permits stable rep- <br />       lication recombinant plasmids latency infected cells. <br />       Proc Natl Acad Sci USA 1984, 81:3806-3810. <br /> 25.   Lupton S, Levine AJ: Mapping genetic elements Epstein-Barr <br />       virus facilitate extrachromosomal persistence       Epstein-Barr virus derived plasmids human cells. Mol Cell <br />       Biol 1985, 5:2533-2542. <br /> 26.   Hirai H, Satoh E, Osawa M, Inaba T, Shimazaki C, Kinoshita S, Naka- <br />       gawa M, Mazda O, Imanishi J: Use EBV-based vector/HVJ-lipo- <br />       complex vector targeted gene therapy EBV <br />       associated neoplasms. Biochem Biophys Res Commun 1997, <br />       241:112-118. <br /> 27.   Tomiyasu K, Satoh E, Oda Y, Nishizaki K, Kondo M, Imanishi J, Mazda <br />       O: Gene transfer vitro vivo Epstein-Barr virus- <br />       based episomal vector results markedly high transient <br />       expression rodent cells. Biochem Biophys Res Commun 1998, <br />       253:733-738. <br /> 28.   Magin-Lachmann C, Kotzamanis G, D&apos;Aiuto L, Cooke H, Huxley C, <br />       Wagner E: vitro vivo delivery intact BAC DNA - <br />       comparison different methods. J Gene Med 2004, 6:195-209. <br /> 29.   Huertas D, Howe S, McGuigan  Huxley C: Expression       human CFTR gene episomal oriP-EBNA1-YACs       mouse cells. Hum Mol Genet 2000, 9:617-629. <br /> 30.   Kreppel F, Kochanek S: Transgene expression proliferating <br />       cells mediated long-term episomally maintained high <br />       capacity adenovirus vectors. J Virol 2004, 78:9-22. <br /> 31.   Suzuki H, Tamai N, Habu Y, Chang MO, Takaku H: Suppression       hepatitis C virus replication baculovirus vector-mediated <br />       short-hairpin RNA expression. FEBS Lett 2008, 582:3085-3089. <br /> 32.   Seo  Abrignani S, Houghton M, Han JH: Small interfering <br />       RNA-mediated inhibition hepatitis C virus replication       human hepatoma cell line Huh-7. J Virol 2003, 77:810-812. <br /> 33.   Kr&#195;&#182;nke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Barten- <br />       schlager R, Frese M: Alternative approaches efficient inhibi- <br />       tion hepatitis C virus RNA replication small interfering <br />       RNAs. J Virol 2004, 78:3436-46. <br /> 34.   Korf M, Jarczak D, Beger C, Manns MP, Kr&#195;&#188;ger M: Inhibition hep- <br />       atitis C virus translation subgenomic replication siR- <br />       NAs directed highly conserved HCV sequence       cellular HCV cofactors. J Hepatol 2005, 43:225-234. <br /> 35.   McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA: <br />       RNA interference adult mice. Nature 2002, 418:38-39. <br /> 36.   Xia H, Mao Q, Paulson HL, Davidson BL: siRNA mediated gene <br />       silencing vitro vivo. Nat Biotechnol 2002, 20:1006-10. <br /> 37.   Condreay JP, Witherspoon SM, Clay WC, Kost TA: Transient       stable gene expression mammalian cells transduced       recombinant baculovirus vector. Proc Natl Acad Sci USA 1999, <br />       96:127-32. <br /> 38.   Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, Wakita T, <br />       Kato N, Shimotohno K: Diverse effects cyclosporine hep- <br />       atitis C virus strain replication. J Virol 2006, 80:4510-4520.                   Publish Bio Med Central 39.   Kaneko H, Suzuki H, Abe T, Miyano-Kurosaki N, Takaku H: Inhibi- <br />       tion HIV-1 replication vesicular stomatitis virus enve-                   scientist read work free charge <br />       lope glycoprotein pseudotyped baculovirus vector-                           &quot;BioMed Central significant development       transduced ribozyme mammalian cells. Biochem Biophys Res                 disseminating results biomedical researc h lifetime.&quot; <br />       Commun 2006, 349:1220-1227. <br /> 40.   Tanaka T, Lau JYN, Mizokami M, Orito E, Tanaka E, Kiyosawa K, Yasui              Sir Paul Nurse, Cancer Research UK <br />    <br /> </body></html>